These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27760790)

  • 1. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.
    Stan MN; Salvi M
    Eur J Endocrinol; 2017 Feb; 176(2):R101-R109. PubMed ID: 27760790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
    Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
    Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
    Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
    J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
    Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
    Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
    Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
    Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
    Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
    Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
    Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.
    Chen J; Chen G; Sun H
    Hormones (Athens); 2021 Jun; 20(2):279-286. PubMed ID: 33783712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential utility of rituximab for Graves' orbitopathy.
    Salvi M; Vannucchi G; Beck-Peccoz P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
    Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
    Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of rituximab in treating steroid-resistant Graves' orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China.
    Zhang Z; Feng X; Guo Y; Kang X; Wang D; Zhang J; Zeng Z; Yuan G
    Heliyon; 2024 Jun; 10(11):e31932. PubMed ID: 38867959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
    Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
    J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Treatment of Graves' Orbitopathy.
    Salvi M; Campi I
    Horm Metab Res; 2015 Sep; 47(10):779-88. PubMed ID: 26361263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy.
    Campi I; Vannucchi G; Salvi M
    Eur J Endocrinol; 2016 Sep; 175(3):R117-33. PubMed ID: 27032693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies for Graves' ophthalmopathy: a network meta-analysis.
    Zhou X; Zhou D; Wang J; Chen G
    Br J Ophthalmol; 2020 Apr; 104(4):551-556. PubMed ID: 31272958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.